Fish Oil and Asthma in House Dust Mite Allergy
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Native populations consuming high amounts of fish suffer less from allergic diseases. The purpose of this study is to determine whether polyunsaturated fatty acids (fish oil) might have a disease modifying influence on asthmatics sensitized to house dust mite.
| Condition | Intervention | Phase |
|---|---|---|
|
Allergic Asthma Bronchial Inflammation House Dust Mite Allergy |
Drug: polyunsatturated fatty acids (fish oil) |
Phase 2 Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | Anti-Inflammatory Effect of Polyunsaturated Fatty Acids in Allergic Asthma After Allergen Challenge |
- lung function, symptom score,exhalative nitric oxide, metacholine testing
- sulfoleucotriens, eosinophilic cationic protein, sputum eosinophils, safety lab parameters (clinical chemistry, hematology, hemostasis)
| Estimated Enrollment: | 23 |
| Study Start Date: | April 2004 |
| Estimated Study Completion Date: | November 2004 |
Most asthmatics suffer from mild disease and non pharmacologic intervention would be beneficial for the majority of these subjects. We investigated the anti-inflammatory potential of polyunsaturated fatty acids (PUFA) in allergic asthma.
In our parallel, double-blinded study, 23 patients allergic to house dust mite were randomly assigned to dietary supplementation with a PUFA enriched fat blend or placebo for five weeks. The verum contained eicosapentaenoic acid (EPA) 450 mg/day, docosahexaenoic acid 180 mg/day, stearidonic acid 60mg/day, and gamma-linolenic acid 60 mg/day; the placebo consisted of mainly unsaturated and monosaturated fatty acids. After three weeks, the patients were challenged with low doses of inhalative house dust mite allergen for two weeks.
Following parameters were determined during low-dose allergen exposure in both groups: exhaled NO (eNO) as a marker of bronchial inflammation, clinical symptoms, FEV1, beta-agonist usage, and bronchial hyperreactivity, sputum eosinophils and sulfoleucotrienes. Compliance with the study protocol was controlled by the determination of PUFAs in plasma and erythrocytes.
Eligibility| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- allergic sensitization to house dust mite as proven by skin test and specific IgE
- normal lung function, episodic asthma
Exclusion Criteria:
- history of hypersensitization towards fish oil, chronic illness, pregnancy
Contacts and Locations
More Information
Publications:
| ClinicalTrials.gov Identifier: | NCT00380926 History of Changes |
| Other Study ID Numbers: | ZAFES-2004-07 |
| Study First Received: | September 25, 2006 |
| Last Updated: | September 28, 2006 |
| Health Authority: | Germany: Federal Ministry of Food, Agriculture and Consumer Protection |
Keywords provided by Johann Wolfgang Goethe University Hospitals:
|
polyunsatturated fatty acids nutrition low-dose allergen challenge exhaled nitric oxide |
Additional relevant MeSH terms:
|
Hypersensitivity Asthma Inflammation Immune System Diseases Bronchial Diseases Respiratory Tract Diseases |
Lung Diseases, Obstructive Lung Diseases Respiratory Hypersensitivity Hypersensitivity, Immediate Pathologic Processes |
ClinicalTrials.gov processed this record on May 21, 2013